EUCTR2004-000585-13-BE进行中（未招募）1 期
A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6–59 Months of Age
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 7,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Age 6 through 59 months of age (not reached their 5th year birthday); (2) Parent/guardian available by telephone; (3) Available for illness visits at clinic or at home during the influenza surveillance period; (4) Written informed consent (and HIPAA authorization for US participants) obtained from the participant’s parent or legal guardian; and (5) Ability of the parent/guardian to understand and comply with the requirements of the protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) History of hypersensitivity to any component of CAIV-T or inactivated influenza vaccine, including egg or egg protein (2) History of hypersensitivity to gentamicin (3) Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy; (4) History of Guillain-Barre syndrome; (5) Medically-diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled) within the previous 42 days by parent report or chart review (e.g., children with recent persistent asthma are excluded), or history of severe asthma; (6) Acute febrile (greater than 100.0 degrees Fahrenheit or greater than 37.8 degrees Celsius oral or equivalent) illness or acute respiratory illness, including cough or sore throat, within three days prior to enrollment; (7) Receipt of an investigational product within 30 days prior to enrollment or expected receipt during this study; (8) Use of aspirin or salicylate-containing products 30 days prior to enrollment or expected receipt during this study; (9) Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanazmivir) within 14 days prior to enrollment or expected receipt during this study; (10) Receipt of any blood product within 90 days prior to vaccination or expected receipt during this study; (11) Administration of any live virus vaccine within 30 days prior to enrollment, or if receipt of another live virus vaccine is expected within 30 days of any study vaccination; (12) Administration of any inactivated vaccine within 14 days prior to enrollment or if receipt of another inactivated vaccine is expected within 14 days of any study vaccination; (13) Close contact who is severely immunocompromised (e.g. transplant recipient); (14) Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study; and (15) Any condition that, in the opinion of the investigator, might interfere with the interpretation or evaluationof the vaccines.
研究者
相似试验
进行中（未招募）
1 期
Assessment of efficacy and safety in patients with non-cancer-related pain and opioid-induced constipation.Opioid-induced constipation (OIC)EUCTR2011-001987-24-SKAstraZeneca AB630
进行中（未招募）
1 期
Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-003158-18-ESBiogen Idec Research Limited290
进行中（未招募）
1 期
A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha-1 Antitrypsin DeficiencyPulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyMedDRA version: 20.0Level: LLTClassification code 10014563Term: Emphysema pulmonarySystem Organ Class: 100000004855EUCTR2013-001870-38-SEGrifols Therapeutics Inc.339
进行中（未招募）
1 期
A study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)Prurigo NodularisMedDRA version: 20.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 100000004858EUCTR2019-004789-17-FRGalderma S.A.240
招募中
3 期
Chronic Migraine in Patients 12 to 17 Years of AgeCTRI/2021/07/034818Eli Lilly and Company India Pvt Ltd